
The Cigna Group
NYSE•CI
CEO: Mr. David Michael Cordani
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 1982-03-31
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Contact Information
Market Cap
$73.42B
P/E (TTM)
11.9
46.8
Dividend Yield
2.2%
52W High
$350.00
52W Low
$239.51
52W Range
Rank17Top 2.9%
6.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$69.75B+9.50%
4-Quarter Trend
EPS
$7.02+164.91%
4-Quarter Trend
FCF
$3.14B-989.52%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Growth Total Revenues reached $202.4B USD, increasing 12% for nine months ended September 30, 2025.
Shareholders' Net Income Surge Shareholders' Net Income $1.97B USD for three months, surging 153% from prior year comparison period.
Evernorth Segment Performance Evernorth adjusted income $5.03B USD, growing 4% for nine months, driven by Pharmacy Benefit Services.
HCSC Divestiture Gain Recognized $79M pre-tax gain on HCSC divestiture for nine months period ending September 30, 2025.
Risk Factors
Rising Medical Cost Trend Medical Care Ratio rose 160 bps for nine months due to higher expected stop loss medical costs.
Premiums Decline Post-Divestiture Premiums fell 21% (3M) and 10% (9M) reflecting significant impact from the HCSC transaction completion.
Debt Capitalization Ratio Debt-to-Capitalization ratio stands at 44.9% as of September 30, 2025, requiring active management.
Investment Portfolio Depreciation Debt securities portfolio shows net unrealized depreciation of $384M due to generally increasing interest rates.
Outlook
Optimization Program Continuation Strategic Optimization Program continues through December 2026, expecting future charges for efficiency improvements.
HCSC Remaining Proceeds Expecting remaining $600M cash proceeds from HCSC transaction in fourth quarter of 2025.
Capital Return Intent Company intends regular quarterly dividends; future declarations subject to ongoing Board review and approval.
Debt Management Strategy Actively monitoring debt obligations, engaging in issuance or redemption activities per capital management strategy.
Peer Comparison
Revenue (TTM)
CVS$394.08B
MCK$387.09B
$321.33B
Gross Margin (Latest Quarter)
GSK73.6%
BMY71.9%
ZTS71.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| HCA | $117.67B | 18.4 | -161.9% | 77.6% |
| BMY | $106.69B | 17.7 | 34.7% | 52.7% |
| MCK | $101.72B | 32.1 | -124.8% | 12.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.0%
Moderate Growth
4Q Net Income CAGR
9.5%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Jan 29, 2026
EPS:$7.90
|Revenue:$69.30B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $69.75B+9.5%|EPS: $7.02+164.9%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $67.23B+11.1%|EPS: $5.76+4.5%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 2, 2025|Revenue: $65.50B+14.4%|EPS: $4.72-586.6%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $247.12B+26.6%|EPS: $12.25-30.3%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $63.69B+29.9%|EPS: $2.65-44.7%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 1, 2024|Revenue: $60.52B+24.6%|EPS: $5.51+11.1%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $57.26B+23.1%|EPS: $-0.97-122.7%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 29, 2024|Revenue: $195.27B+8.2%|EPS: $17.39-18.9%Miss